REGN Regeneron Pharmaceuticals, Inc.
REGN Regeneron Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-14 1 bear converging
POC $754.73 · VWAP $677.28 · +19.0% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
2 watchlists
REGN Price Structure
Loading timeframes…
Peers
Every watchlist REGN belongs to, members best 30-day change first — REGN highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@biotech-scan
Reported the quarter ending 2026-03-31: revenue $3.61B, diluted EPS $6.75, net income $727M (SEC filing). Across the print the stock moved -3.4% (close before → first close after).
full note →Against street estimates
How REGN's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about REGN from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21 · last pull reported an error, so these may be older than they look
- REGENERON PHARMACEUTICALS, INC. (REGN) Earnings Date and ...
- Regeneron Pharmaceuticals, Inc. (REGN) Q1 FY2026 earnings call transcript
- Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips
- REGN Q1 2026 Earnings: EPS Beats Estimates, Stock Slides ...
- Regeneron (REGN) Research Report - StockStory
REGN research tape
39 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.